

Amniotics today announces the outcome of the exercise of warrants of series T01

Amniotics AB (publ) (“Amniotics” or the “Company”) conducted a unit issue of shares and warrants of series T01 (the “warrants”) in connection with the listing on Nasdaq First North Growth Market on July 6, 2021. The units issued in connection with the listing consisted of shares and warrants of series T01 (the “warrants”). The exercise period for the warrants lasted from May 5, 2022, to May 19, 2022. No notifications have been made for the exercise of the warrants.

One (1) warrant entitled the holder to subscribe for one (1) new share in Amniotics at a subscription price set to 23.50 SEK. As the subscription price exceeds the prevailing share price, no notifications have been made for the exercise of the warrants.

Advisers

Redeye AB acts as financial adviser and Nordic Issuing AB acts as the issuing agent in the Rights Issue.

For more information please contact

Kåre Engkilde
CEO, Amniotics AB
Phone: +46 (0) 723 27 85 20
Email: ke@amniotics.com
or
Johnny Humaloja
CFO, Amniotics AB
Phone: +46 (0) 735 0668 56
Email: jh@amniotics.com

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has its headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Learn more at www.amniotics.com.

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

Attachments

Amniotics today announces the outcome of the exercise of warrants of series TO1